Reporter brief
COVFIS-HOME: A Phase 2 Placebo-Controlled Pilot Study in COVID-19 of Fisetin to Alleviate Dysfunction and Decrease Complications in At-Risk Outpatients
What happened
Trial registry update: COMPLETED. Results are posted in the registry; assessment pending.
Why it matters
Assessment pending; this report does not establish a change in evidence.
What it does NOT prove
- The abstract does not report primary outcome results or effect sizes, making it impossible to determine whether fisetin actually reduced complications or by how much.
- Sample size is not reported, preventing assessment of statistical power or reliability of any estimates.
- As a pilot study, findings may not generalize to broader COVID-19 populations or predict efficacy in larger confirmatory trials.
Study design and sample
Rct; Human.
Not recorded.
- Design
- Rct
- Sample
- —
- Journal
- James L. Kirkland, MD, PhD
- Published
- Aug 1, 2023
Effect size
Not recorded.
Caveats
- Assessment: Unassessed.
- Only the source material recorded on this evidence page was assessed.
Conflicts and funding
Not recorded.
Previous evidence
See the Senolytics timeline and recorded assessment for prior evidence.
Primary source
Cancel Death charts and briefs may be reproduced editorially with attribution to CancelDeath.com. This brief is generated from the primary recorded source facts and assessment. Its review status is shown below; verify quotations against the paper before publication.